Myriad Medical Technologies stock is still good. While all companies in the pharma space are worried about collective purchasing, pharma companies in the a-share market are moving towards differentiation, as this will accelerate technological innovation in the business. This is an era of testing success, the core is who can through the industry cycle, with sustained and stable performance, as well as the core of the key technology to support the product, to promote the rapid development of enterprises. Only true technology industry leaders have the ability to leapfrog industry cycles.On August 25, as a medical device leader, Myriad Medical released its half-yearly report, with revenues of 12.778 billion yuan, an increase of 20.96% year-on-year, and a net profit of 4.344 billion yuan, an increase of 25.79% year-on-year; after deducting the items of 4.309 billion yuan, an increase of 28% year-on-year. Myriad's semiannual report was significant, with good results and solid growth.
Myray Medical has been posting high growth results for the past few years. The data is the best way to break the gloom and boost investor confidence. In fact, before and after the release of the half-yearly report, the share price of Myriad Pharmaceuticals significantly higher. As of August 27, the price of Myriad Medical shares was 323.25 yuan, rebounding 16.24% from the low in just one week, beginning the return of the leading value of medical equipment. Against the backdrop of high performance growth and high valuation returns, Myriad Medical is targeting the global vision pattern and layout of a world-class medical device company, with a high focus on research and development, and a strong executive presence that continues to explore new tracks. As well as ? Become a core force in protecting human health? the great conscience of the vision.
In 2020, affected by the epidemic, the world will set off a new wave of new medical infrastructure construction, which will be on the demand side for China's medical device? Golden Decade? provide stronger support. In the post-New Crown Pneumonia era, governments are facing greater financial pressures, and purchases by governments and private medical groups are more price-sensitive. This is a great opportunity for Myriad Medical, which has high operational efficiency, cost-effective products, complete product lines, and overall solution advantages. Meanwhile, as a leading medical device in China, Myriad Medical is also expanding its business. For example, Myriad will focus on cultivating niche circuits such as minimally invasive surgery, animal medicine, and AED, and actively explore seed businesses such as ultra-high-end color ultrasound, molecular diagnostics, and orthopedics, which are all growth opportunities for the future.
In the long history of business civilization, there has always been a rule of survival in the rapidly changing environment: focus on the long term, do the hard and right thing, and wait for the rose of time to blossom. Following the rules is not only a fundamental way for investors to cultivate themselves, but also an inevitable path for excellent enterprises to grow. Myriad Medical, as Ningde Times, from the gross index through the Ning portfolio industry's super leader. After 30 years of hard work, Myriad Medical has become the nation's number one medical organization.